References
- Olsen EA, Messenger AG, Shapiro J et al. Evaluation and treatment of male and female pattern hair loss. J. Am. Acad. Dermatol. 52, 301–311 (2005).
- Wang TL, Zhou C, Shen YW et al. Prevalence of androgenetic alopecia in China: a community-based study in six cities. Br. J. Dermatol. 162(4), 843–847 (2010).
- Gonzalez ME, Cantatore-Francis J, Orlow SJ. Androgenetic alopecia in the paediatric population: a retrospective review of 57 patients. Br. J. Dermatol. 163(2), 378–385 (2010).
- Hillmer AM, Freudenberg J, Myles S et al. Recent positive selection of a human androgen receptor/ectodysplasin A2 receptor haplotype and its relationship to male pattern baldness. Hum. Genet. 126(2), 255–264 (2009).
- Rathnayake D, Sinclair R. Male androgenetic alopecia. Expert Opin. Pharmacother. 11(8), 1295–1304 (2010).
- Goodarzi HR, Abbasi A, Saffari M, Tabei MB, Noori Daloii MR. MicroRNAs take part in pathophysiology and pathogenesis of male pattern baldness. Mol. Biol. Rep. 37(6), 2959–2965 (2010).
- Arias-Santiago S, Arrabal-Polo MA, Buendía-Eisman A et al. Androgenetic alopecia as an early marker of benign prostatic hyperplasia. J. Am. Acad. Dermatol. 66(3), 401–408 (2012).
- Lynn R, Krunic A. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction? Dermatol. Ther. 23(5), 544–546 (2010).